Armistice Capital LLC Takes Position in Genelux Co. (NASDAQ:GNLX)

Armistice Capital LLC acquired a new position in shares of Genelux Co. (NASDAQ:GNLX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 900,000 shares of the company's stock, valued at approximately $1,755,000. Armistice Capital LLC owned about 2.62% of Genelux at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Woodward Diversified Capital LLC grew its stake in Genelux by 2,326.2% in the fourth quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company's stock valued at $15,163,000 after acquiring an additional 1,037,663 shares during the period. Clarity Capital Partners LLC bought a new stake in Genelux during the 4th quarter worth approximately $364,000. LifeSteps Financial Inc. boosted its holdings in shares of Genelux by 26.6% in the first quarter. LifeSteps Financial Inc. now owns 44,309 shares of the company's stock valued at $285,000 after buying an additional 9,301 shares during the period. SageView Advisory Group LLC bought a new stake in shares of Genelux during the first quarter worth $121,000. Finally, Vanguard Group Inc. lifted its position in Genelux by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company's stock valued at $6,578,000 after acquiring an additional 24,220 shares in the last quarter. Institutional investors own 37.33% of the company's stock.

Genelux Price Performance

GNLX stock traded up $0.06 during mid-day trading on Friday, reaching $2.17. The company had a trading volume of 30,343 shares, compared to its average volume of 186,740. The company has a market capitalization of $74.54 million, a price-to-earnings ratio of -2.24 and a beta of -1.55. Genelux Co. has a 52 week low of $1.60 and a 52 week high of $26.07. The stock has a 50 day simple moving average of $2.19 and a two-hundred day simple moving average of $3.15.

Genelux (NASDAQ:GNLX - Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, equities analysts predict that Genelux Co. will post -0.9 EPS for the current year.

Wall Street Analysts Forecast Growth

GNLX has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and issued a $32.00 price target on shares of Genelux in a report on Thursday, August 15th. Roth Mkm started coverage on Genelux in a research report on Tuesday, August 27th. They set a "buy" rating and a $10.00 price target for the company. Roth Capital upgraded shares of Genelux to a "strong-buy" rating in a report on Tuesday, August 27th. Finally, Benchmark reduced their target price on shares of Genelux from $30.00 to $25.00 and set a "speculative buy" rating for the company in a report on Friday, May 31st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $22.33.

Insider Activity

In other news, major shareholder Aladar Szalay sold 51,630 shares of the company's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $2.11, for a total value of $108,939.30. Following the sale, the insider now directly owns 1,048,191 shares of the company's stock, valued at approximately $2,211,683.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 331,062 shares of company stock valued at $736,831 in the last quarter. Company insiders own 9.30% of the company's stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.